Rasagilinum

E Vicipaedia
Jump to navigation Jump to search
Esculaap4.svg
Cave: notitiae huius paginae nec praescriptiones nec consilia medica sunt.


Rasagilinum
Rasagilinum
Rasagilinum
Natura chemica
Formula chemica C12H13N
Massa molaris 171.238 g/mol
PubChem 3052776
DrugBank DB01367
Natura pharmacologica
Codex ATC N04BD02 (WHO)
Tempus semivitae biologicum 3 h
Metabolismus iecore (hepaticus): CYP1A2
Excretio renibus, faecibus
Ad usum therapeuticum
Applicatio per os
MedlinePlus a606017 (Anglice)

Rasagilinum est medicamentum pharmaceuticum et inhibitor monoaminorum oxidasis B irreversibilis[1]. Substantia in morbo Parkinson tractando et maturo[2] et in cursibus progressivis.

Natura Rasagilini[recensere | fontem recensere]

Natura chemica[recensere | fontem recensere]

Nomen suum est (R)-N-prop-2-inyl-2,3-dihydro-1H-inden-1-aminum. Massa molaris sua 171.238 g/mol.

Natura pharmacologica[recensere | fontem recensere]

Rasagilinum est MAO-B inhibitor irreversibilis et medicamentum therapia morbi Parkinson et maturi et progressivi. Codex ATC est N04BD02 (WHO). Inhibitio monoaminorum oxidasis B potentissima est, etenim quinquies, decies quam Selegilino.

Effectus Rasagilini[recensere | fontem recensere]

Interactiones[recensere | fontem recensere]

Consumptio simul Rasagilini et cuiusvis inhibitoris reabsorptionis serotonini (per exemplum: sertralinum) periculo syndromatis serotonini causa saepe non commendatur[3][4], quamquam investigatio Canadiensis syndroma serotoni raro esse dixit, donec doses inhibitoris reabsorptionis serotonini parve deligantur[5].

Notae[recensere | fontem recensere]

  1. Oldfield V., Keating G. M., Perry C. M. (2007). "Rasagiline: a review of its use in the management of Parkinson's disease". Drugs 67 (12): 1725-47 
  2. Hattori N., Takeda A., Takeda S., Nishimura A., Kitagawa T., Mochizuki H., Nagai M., Takahashi R. (2018). "Rasagiline monotherapy in early Parkinson's disease: A phase 3, randomized study in Japan". Parkinsonism Relat Disord: doi: 10.1016/j.parkreldis.2018.08.024 
  3. Hébant B., Guillaume M., Desbordes M., Gaillon G., Maltête D., Lefaucheur R. (2016). "Combination of paroxetine and rasagiline induces serotonin syndrome in a parkinsonian patient". Rev Neurol (Paris) 172 (12): 788-9 
  4. Duval F., Flabeau O., Razafimahefa J., Spampinato U., Tison F. (2013). "Encephalophaty associated with rasagiline and sertraline in Parkinson's disease: possible serotonin syndrome". Mov Disord 28 (10): 1464 
  5. Aboukarr A., Giudice M. (2018). "Interaction between Monoamine Oxidase B Inhibitors and Selective Serotonin Reuptake Inhibitors". Can J Hosp Pharm 71 (3): 196-207 

Nexus interni

Nexus externi[recensere | fontem recensere]